Undervalued Zai Lab on Licensing Binge to Boost Cancer Treatment Portfolio

With $860 million in new cash from a recent share sale, company seeks to accelerate approval and rollout of new cutting-edge treatments from abroad Key takeaways: Zai Lab’s revenue should continue to surge on new product approvals and inclusion of a core product on the National Reimbursement Drug List Company’s losses could continue to balloon as it pursues expensive new licensing deals at the cost of near-term profits By Richard Barbarossa Cancer and autoimmune drug specialist Zai Lab Ltd.(Nasdaq: ZLAB; 9688.HK) is poised to accelerate approval of new medicines and…

Read MORE »

CStone Finds Tonic in Steady Stream of Drug Approvals, Licensing Deals

Cancer drug specialist reported its first significant revenue in 2020, following a string of milestones capped by a $200 million investment from Pfizer Key takeaways: Strong upfront licensing fees helped CStone post its first-ever significant revenues and narrowing losses in 2020 The company is eying new approvals for more uses of its cancer drugs as big-name global pharma companies pump it up with cash By Richard Barbarossa CStone Pharmaceuticals Co. Ltd (2616.HK), a Chinese maker of immuno-oncology therapies and precision medicines, is moving closer to profitability after its losses narrowed…

Read MORE »

Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own

Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology and immunology business will more than triple on new approvals and more direct control over its sales and marketing Stiff competition in cancer drugs and divestiture of its profitable but non-core OTC business could result in continued net losses By Richard Barbarossa Hutchison China MediTech Ltd. (Nasdaq: HCM; HCM.L), a leading Chinese maker of cancer drugs backed by Hong Kong…

Read MORE »